Banco Santander S.A. Reduces Holdings in Illumina, Inc. (NASDAQ:ILMN)

Banco Santander S.A. lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 5.4% in the 3rd quarter, Holdings Channel reports. The firm owned 21,264 shares of the life sciences company’s stock after selling 1,210 shares during the quarter. Banco Santander S.A.’s holdings in Illumina were worth $2,773,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ILMN. Versant Capital Management Inc boosted its position in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the period. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina in the 2nd quarter worth $34,000. Massmutual Trust Co. FSB ADV raised its holdings in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Illumina during the 2nd quarter worth approximately $61,000. Finally, Mizuho Securities Co. Ltd. purchased a new stake in shares of Illumina during the 2nd quarter valued at $63,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ILMN. Piper Sandler decreased their price target on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. StockNews.com initiated coverage on Illumina in a report on Thursday, August 29th. They set a “buy” rating for the company. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Robert W. Baird raised their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, TD Cowen boosted their price objective on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $164.00.

Illumina Trading Up 4.1 %

Shares of Illumina stock opened at $137.09 on Friday. Illumina, Inc. has a 1-year low of $93.51 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock has a market cap of $21.74 billion, a P/E ratio of -13.76 and a beta of 1.13. The stock’s 50 day simple moving average is $140.39 and its 200-day simple moving average is $124.61.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the previous year, the company posted $0.33 EPS. The company’s revenue was down 3.5% compared to the same quarter last year. Analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.